Once-Daily Tapinarof Cream Shows Strong 60-Week Results in Young Children With Eczema

A new phase 3 clinical trial has delivered some of the most encouraging long-term evidence yet for treating eczema in young children, showing that a once-daily nonsteroidal cream dramatically outperformed a placebo and continued to work for more than a year of continuous use. The drug, tapinarof, is an aryl hydrocarbon receptor agonist that is already approved in Japan for patients aged 12 and older, but the new study focused on a younger and often underserved group: Japanese children aged 2 to 11 years with atopic dermatitis. The results, published in the Journal of Cutaneous Immunology and Allergy, suggest that a steroid-free topical option with a fundamentally different mechanism of action could soon extend to the youngest patients who bear a disproportionate share of the disease burden.

Atopic dermatitis is far more than a cosmetic nuisance. It is a chronic, relapsing inflammatory skin disease characterized by eczematous lesions and intense itching, driven by a tangle of genetic predisposition, environmental triggers, skin barrier dysfunction, and immune dysregulation. While it affects roughly 7 to 10 percent of adults worldwide, prevalence in children can reach 25 percent, and Japanese surveys have reported rates as high as 27 percent among preschool children. The consequences ripple through entire households: disrupted sleep, impaired quality of life for children and their guardians, and the daily grind of applying multiple treatments. For most patients, topical therapies remain the mainstay of management, yet the workhorse drugs, topical corticosteroids, carry well-known limitations for long-term use, including the risk of skin atrophy.

Treatment guidelines in Japan emphasize reaching and maintaining a stable state in which signs and symptoms are absent or minimal without interfering with daily activities. Although biologics and other systemic therapies exist for refractory moderate-to-severe disease, the vast majority of children depend on creams and ointments. In recent years, nonsteroidal options such as Janus kinase inhibitors and phosphodiesterase-4 inhibitors have broadened the arsenal, but clinicians continue to call for effective topical agents with new mechanisms. Tapinarof answers that call with an unusual biological strategy: rather than suppressing inflammation broadly, it activates the aryl hydrocarbon receptor, a transcription factor that downregulates inflammatory cytokines implicated in atopic dermatitis while simultaneously upregulating components of the skin barrier.

That dual action is what makes the drug scientifically interesting. By engaging the aryl hydrocarbon receptor, tapinarof appears to improve measurable markers of barrier health, including stratum corneum hydration and transepidermal water loss, according to earlier clinical work in Japanese patients. The compound also activates the nuclear factor erythroid 2 related factor 2 pathway, which ramps up antioxidant enzymes and reduces oxidative stress in the skin. In effect, the drug does not merely quiet inflammation; it appears to help rebuild the defective barrier that lies at the heart of the disease. Tapinarof cream 1 percent is already approved for atopic dermatitis in patients aged 2 and older in the United States and the United Arab Emirates, and for patients 12 and older in Japan, where a phase 2 trial in younger children identified the 0.5 percent strength as the preferred formulation for this age group.

The new phase 3 trial, conducted between August 2023 and March 2025 at 27 sites in Japan, enrolled 162 children and was structured in two parts. The first was an 8-week, double-blind, vehicle-controlled period in which patients were randomized 2:1 to tapinarof cream 0.5 percent or an inactive vehicle cream, with allocation balanced by age category and baseline disease severity. The second was a 52-week open-label extension in which 151 patients who continued into that phase all received active treatment. Families applied a thin layer of cream once daily to all eczema lesions, excluding the hairy scalp, and children were required to have mild to severe disease at baseline, with an Eczema Area and Severity Index score of at least 5 and 5 to 30 percent of body surface area affected. The two groups were well matched, with mean baseline EASI scores of about 10.9 and 10.7 and roughly 60 percent of participants rated as having moderate disease.

The headline result was unambiguous. At week 8, 52.59 percent of children treated with tapinarof achieved a 75 percent or greater improvement in their EASI score, the trial’s primary endpoint, compared with just 12.60 percent of those on vehicle cream, a difference of 40 percentage points with a p value below 0.0001. On the key secondary endpoint, 26.2 percent of tapinarof-treated children reached treatment success on the Investigator’s Global Assessment, meaning their skin was rated clear or almost clear with at least a two-grade improvement, versus only 1.8 percent on vehicle. The mean percent reduction in EASI score was 68.28 percent with tapinarof compared with 23.01 percent with vehicle. Patient-reported measures reinforced the clinical picture: improvements in the Patient-Oriented Eczema Measure appeared from week 2 onward, and itch scores, recorded twice daily in diaries by guardians, fell rapidly after treatment began.

Perhaps the most striking findings emerged over the long haul. Among children who stayed on tapinarof, the EASI-75 response rate climbed from 53.4 percent at week 8 to 75.8 percent at week 32 and 80.2 percent at week 60, while global assessment treatment success rose from 24.3 percent to 48.5 percent and then 56.3 percent over the same span. Children who started on vehicle and switched to the active cream showed a rapid catch-up, reaching EASI-75 rates of 84.8 percent at week 32 and 82.8 percent at week 60. Notably, most patients continued applying the cream even after their lesions cleared, with roughly 80 percent accumulating at least 48 weeks of exposure, and the benefits were maintained without apparent differences between the 2-to-6 and 7-to-11 age groups. Rescue therapy with topical corticosteroids was needed by only about 20 percent of patients during the extension period.

The safety profile proved equally reassuring. Across the entire 60 weeks, no treatment-related serious adverse events were reported, and all treatment-related events were mild or moderate. During the double-blind period, adverse events occurred at similar rates in both groups, driven largely by everyday childhood infections such as nasopharyngitis and influenza. The most common treatment-related events with tapinarof were folliculitis and acne, including application-site folliculitis in 4.5 percent and acne in 3.9 percent of patients over the full trial. The authors attribute these follicular events to increased cornification within hair follicles, a downstream consequence of the drug’s upregulation of barrier proteins such as filaggrin, hornerin, and involucrin, giving them a morphology resembling keratosis pilaris. Only 2.6 percent of patients discontinued due to adverse events in the overall period, and pharmacokinetic sampling showed tapinarof plasma concentrations below the detection limit of 50 picograms per milliliter in at least 80 percent of children at every time point, confirming minimal systemic absorption.

The trial does have limitations worth noting. Most enrolled children had mild or moderate disease, and only four had severe eczema, so the findings may not fully generalize to the most severely affected patients. The comparator was vehicle cream rather than an active standard of care, leaving tapinarof’s superiority over existing topical therapies untested, and children under 2 years of age, in whom the disease is also prevalent, were not included, although a separate 52-week trial in patients aged 3 to 24 months is now underway in Japan. Long-term efficacy analyses also relied on observed cases without imputation and allowed treatment interruptions after clearance. Still, the overall message is clear: a once-daily, steroid-free cream that harnesses the aryl hydrocarbon receptor to both calm inflammation and rebuild the skin barrier delivered substantial, durable, and well-tolerated benefit in young children over more than a year of use. For families exhausted by the cycle of flares, steroids, and sleepless nights, tapinarof may soon offer a genuinely new way forward.

Subject of Research: Efficacy and safety of topical tapinarof cream in Japanese pediatric patients with atopic dermatitis

Article Title: Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period

Article References: Igarashi, A., Tsuji, G., Murata, R., Fukasawa, S., & Yamane, S. (2026). Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Article 17307. https://doi.org/10.3389/jcia.2026.17307

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17307

Keywords: tapinarof, atopic dermatitis, aryl hydrocarbon receptor, pediatric patients, phase 3 trial, topical treatment, eczema, EASI-75, skin barrier, nonsteroidal therapy, folliculitis, Japan